| Name | Title | Contact Details |
|---|
At Zevtron, we develop solutions to help forward thinking organizations more efficiently and responsibly facilitate the use of electricity for transportation fuel. We are committed to provide our customers with reliable and economically viable plug-in electric vehicle charging solutions to help accelerate the installation of plug-in vehicle infrastructure.
The Faulkner Organization is a family-owned automotive dealership group based in Pennsylvania, founded in 1932. With a legacy of over nine decades, it operates 31 dealerships across Central and Southeastern Pennsylvania, representing 22 vehicle brands. The company specializes in the sale and service of new and pre-owned vehicles. Their offerings include automotive sales, maintenance and repair services, financing and insurance assistance, genuine parts supply, and body shop repair services. The Faulkner Organization is committed to customer satisfaction, employee development, and maintaining high ethical standards in all business dealings.
Manhattan School of Music (MSM) is a renowned private music conservatory located in New York City, founded in 1917-1918 by pianist and philanthropist Janet D. Schenck. Originally established as the Neighborhood Music School in East Harlem, MSM has built a strong reputation for excellence in music education, influenced by notable artists like Pablo Casals and Harold Bauer. The school offers a range of academic programs, including Bachelor of Music, Master of Music, and Doctor of Musical Arts degrees. MSM specializes in classical and jazz performance, composition, conducting, and music education, and features a prominent opera program. Its campus in Morningside Heights includes instructional spaces, performance venues, and a residence hall, with facilities like the Hubbard Recital Hall, which houses a distinguished Aeolian-Skinner organ. MSM attracts a diverse student body of aspiring professional musicians from around the world, providing rigorous training and numerous performance opportunities. The institution is dedicated to fostering professional musicianship in both classical and jazz traditions.
Kaufman Dolowich LLP is a nationally recognized litigation law firm that has been serving the business and insurance communities since 1986. With 13 offices across the United States, Bermuda, and the United Kingdom, the firm has expanded from a boutique labor and employment practice into a comprehensive legal service provider. It offers a wide range of services, including labor and employment law, insurance coverage and litigation, professional liability, construction law, and more. The firm is known for its client-centered approach, focusing on developing innovative and cost-effective legal strategies tailored to various industries and complex legal matters. Kaufman Dolowichs attorneys are recognized leaders in their fields, often sharing their expertise at national conferences. The firm has a diverse clientele, including businesses and insurance carriers of all sizes, and has received accolades for its workplace culture, including multiple Mansfield Certification recognitions and being named among the “Best Companies to Work For” by U.S. News & World Report.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.